Acorda Therapeutics, Inc.
ACOR · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | -457.04% | -831.64% | -981.44% | -1,172.40% |
| EV / EBITDA | 19.48 | -13.75 | -3.34 | -2.99 |
| Quality | ||||
| ROIC | -25.57% | -21.89% | -17.98% | -14.05% |
| Gross Margin | 60.86% | 74.42% | 68.40% | 78.09% |
| Cash Conversion Ratio | 0.06 | 0.32 | 0.40 | 0.61 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.05% | -8.14% | -12.46% | -31.28% |
| Free Cash Flow Growth | 32.35% | 49.30% | 36.48% | 70.08% |
| Safety | ||||
| Net Debt / EBITDA | 19.11 | -13.50 | -3.24 | -2.90 |
| Interest Coverage | -0.74 | -1.49 | -2.57 | -2.84 |
| Efficiency | ||||
| Inventory Turnover | 2.85 | 2.38 | 2.20 | 1.17 |
| Cash Conversion Cycle | 66.48 | 74.76 | 108.33 | 212.62 |